{"pmid":32416961,"title":"Biochemical characterization of SARS-CoV-2 nucleocapsid protein.","text":["Biochemical characterization of SARS-CoV-2 nucleocapsid protein.","The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. In this study, we expressed the N protein of SARS-CoV-2 and characterized its biochemical properties. Static light scattering, size exclusive chromatography, and small-angle X-ray scattering (SAXS) showed that the purified N protein is largely a dimer in solution. CD spectra showed that it has a high percentage of disordered region at room temperature while it was best structured at 55 degrees C, suggesting its structural dynamics. Fluorescence polarization assay showed it has non-specific nucleic acid binding capability, which raised a concern in using it as a diagnostic marker. Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics.","Biochem Biophys Res Commun","Zeng, Weihong","Liu, Guangfeng","Ma, Huan","Zhao, Dan","Yang, Yunru","Liu, Muziying","Mohammed, Ahmed","Zhao, Changcheng","Yang, Yun","Xie, Jiajia","Ding, Chengchao","Ma, Xiaoling","Weng, Jianping","Gao, Yong","He, Hongliang","Jin, Tengchuan","32416961"],"abstract":["The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. In this study, we expressed the N protein of SARS-CoV-2 and characterized its biochemical properties. Static light scattering, size exclusive chromatography, and small-angle X-ray scattering (SAXS) showed that the purified N protein is largely a dimer in solution. CD spectra showed that it has a high percentage of disordered region at room temperature while it was best structured at 55 degrees C, suggesting its structural dynamics. Fluorescence polarization assay showed it has non-specific nucleic acid binding capability, which raised a concern in using it as a diagnostic marker. Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics."],"journal":"Biochem Biophys Res Commun","authors":["Zeng, Weihong","Liu, Guangfeng","Ma, Huan","Zhao, Dan","Yang, Yunru","Liu, Muziying","Mohammed, Ahmed","Zhao, Changcheng","Yang, Yun","Xie, Jiajia","Ding, Chengchao","Ma, Xiaoling","Weng, Jianping","Gao, Yong","He, Hongliang","Jin, Tengchuan"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32416961","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.bbrc.2020.04.136","keywords":["antigenicity","covid-19","nucleocapsid protein","sars-cov-2","saxs","structure and function"],"topics":["Mechanism"],"weight":1,"_version_":1667058206853038080,"score":9.490897,"similar":[{"pmid":32105468,"pmcid":"PMC7094172","title":"Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","text":["Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases.","J Med Chem","Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon","32105468"],"abstract":["Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases."],"journal":"J Med Chem","authors":["Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105468","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1021/acs.jmedchem.9b01913","e_drugs":["5-benzyloxygramine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490789691392,"score":294.03992},{"pmid":32267220,"title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","text":["Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.","Emerg Infect Dis","Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L","32267220"],"abstract":["A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies."],"journal":"Emerg Infect Dis","authors":["Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267220","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3201/eid2607.200841","keywords":["covid-19","elisa","hcov","rbd","sars-cov-2","severe acute respiratory syndrome coronavirus 2","antibodies","coronavirus","coronavirus disease 2019","human coronavirus","neutralization","nucleocapsid protein","receptor-binding domain","respiratory infections","serologic analysis","spike protein","viruses","zoonoses"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491931590658,"score":288.77554},{"pmid":32292212,"pmcid":"PMC7152864","title":"Photopolarimetrical properties of coronavirus model particles: spike proteins number influence.","text":["Photopolarimetrical properties of coronavirus model particles: spike proteins number influence.","Coronavirus virions have spherical shape surrounded by spike proteins. The coronavirus spike proteins are very effective molecular mechanisms, which provide the coronavirus entrance to the host cell. The number of these spikes is different; it dramatically depends on external conditions and determines the degree of danger of the virus. A larger number of spike proteins makes the virus infectivity stronger. This paper describes a mathematical model of the shape of coronavirus virions. Based on this model, the characteristics of light scattered by the coronavirus virions were calculated. It was found two main features of coronavirus model particles in the spectral region near 200nm: a minimum of intensity and a sharp leap of the linear polarization degree. The effect of the spike protein number on the intensity and polarization properties of the scattered light was studied. It was determined that when the number of spike proteins decreases, both the intensity minimum and the position of the linear polarization leap shift to shorter wavelengths. This allows us to better evaluate the shape of the coronavirus virion, and, therefore, the infectious danger of the virus. It was shown that the shorter the wavelength of scattered light, the more reliably one can distinguish viruses from non-viruses. The developed model and the light scattering simulations based on it can be applied not only to coronaviruses, but also to other objects of a similar structure, for example, pollen.","J Quant Spectrosc Radiat Transf","Petrov, Dmitry","32292212"],"abstract":["Coronavirus virions have spherical shape surrounded by spike proteins. The coronavirus spike proteins are very effective molecular mechanisms, which provide the coronavirus entrance to the host cell. The number of these spikes is different; it dramatically depends on external conditions and determines the degree of danger of the virus. A larger number of spike proteins makes the virus infectivity stronger. This paper describes a mathematical model of the shape of coronavirus virions. Based on this model, the characteristics of light scattered by the coronavirus virions were calculated. It was found two main features of coronavirus model particles in the spectral region near 200nm: a minimum of intensity and a sharp leap of the linear polarization degree. The effect of the spike protein number on the intensity and polarization properties of the scattered light was studied. It was determined that when the number of spike proteins decreases, both the intensity minimum and the position of the linear polarization leap shift to shorter wavelengths. This allows us to better evaluate the shape of the coronavirus virion, and, therefore, the infectious danger of the virus. It was shown that the shorter the wavelength of scattered light, the more reliably one can distinguish viruses from non-viruses. The developed model and the light scattering simulations based on it can be applied not only to coronaviruses, but also to other objects of a similar structure, for example, pollen."],"journal":"J Quant Spectrosc Radiat Transf","authors":["Petrov, Dmitry"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292212","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jqsrt.2020.107005","keywords":["computer simulation","coronavirus","intensity","light scattering","polarization","shape matrices"],"weight":0,"_version_":1666138494531010561,"score":288.72174},{"pmid":32206694,"pmcid":"PMC7085496","title":"Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).","text":["Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV).","The emergence of 2019 novel coronavirus (2019-nCoV) is of global concern and might have emerged from RNA recombination among existing coronaviruses. CoV spike (S) protein which is crucial for receptor binding, membrane fusion via conformational changes, internalization of the virus, host tissue tropism and comprises crucial targets for vaccine development, remain largely uncharacterized. Therefore, the present study has been planned to determine the sequence variation, structural and antigenic divergence of S glycoprotein which may be helpful for the management of 2019-nCoV infection. The sequences of spike glycoprotein of 2019-nCoV and SARS coronavirus (SARS-CoV) were used for the comparison. The sequence variations were determined using EMBOSS Needle pairwise sequence alignment tools. The variation in glycosylation sites was predicted by NetNGlyc 1.0 and validated by N-GlyDE server. Antigenicity was predicted by NetCTL 1.2 and validated by IEDB Analysis Resource server. The structural divergence was determined by using SuperPose Version 1.0 based on cryo-EM structure of the SARS coronavirus spike glycoprotein. Our data suggests that 2019-nCoV is newly spilled coronavirus into humans in China is closely related to SARS-CoV, which has only 12.8% of difference with SARS-CoV in S protein and has 83.9% similarity in minimal receptor-binding domain with SARS-CoV. Addition of a novel glycosylation sites were observed in 2019-nCoV. In addition, antigenic analysis proposes that great antigenic differences exist between both the viral strains, but some of the epitopes were found to be similar between both the S proteins. In spite of the variation in S protein amino acid composition, we found no significant difference in their structures. Collectively, for the first time our results exhibit the emergence of human 2019-nCoV is closely related to predecessor SARS-CoV and provide the evidence that 2019-nCoV uses various novel glycosylation sites as SARS-CoV and may have a potential to become pandemic owing its antigenic discrepancy. Further, demonstration of novel Cytotoxic T lymphocyte epitopes may impart opportunities for the development of peptide based vaccine for the prevention of 2019-nCoV.","Virusdisease","Kumar, Swatantra","Maurya, Vimal K","Prasad, Anil K","Bhatt, Madan L B","Saxena, Shailendra K","32206694"],"abstract":["The emergence of 2019 novel coronavirus (2019-nCoV) is of global concern and might have emerged from RNA recombination among existing coronaviruses. CoV spike (S) protein which is crucial for receptor binding, membrane fusion via conformational changes, internalization of the virus, host tissue tropism and comprises crucial targets for vaccine development, remain largely uncharacterized. Therefore, the present study has been planned to determine the sequence variation, structural and antigenic divergence of S glycoprotein which may be helpful for the management of 2019-nCoV infection. The sequences of spike glycoprotein of 2019-nCoV and SARS coronavirus (SARS-CoV) were used for the comparison. The sequence variations were determined using EMBOSS Needle pairwise sequence alignment tools. The variation in glycosylation sites was predicted by NetNGlyc 1.0 and validated by N-GlyDE server. Antigenicity was predicted by NetCTL 1.2 and validated by IEDB Analysis Resource server. The structural divergence was determined by using SuperPose Version 1.0 based on cryo-EM structure of the SARS coronavirus spike glycoprotein. Our data suggests that 2019-nCoV is newly spilled coronavirus into humans in China is closely related to SARS-CoV, which has only 12.8% of difference with SARS-CoV in S protein and has 83.9% similarity in minimal receptor-binding domain with SARS-CoV. Addition of a novel glycosylation sites were observed in 2019-nCoV. In addition, antigenic analysis proposes that great antigenic differences exist between both the viral strains, but some of the epitopes were found to be similar between both the S proteins. In spite of the variation in S protein amino acid composition, we found no significant difference in their structures. Collectively, for the first time our results exhibit the emergence of human 2019-nCoV is closely related to predecessor SARS-CoV and provide the evidence that 2019-nCoV uses various novel glycosylation sites as SARS-CoV and may have a potential to become pandemic owing its antigenic discrepancy. Further, demonstration of novel Cytotoxic T lymphocyte epitopes may impart opportunities for the development of peptide based vaccine for the prevention of 2019-nCoV."],"journal":"Virusdisease","authors":["Kumar, Swatantra","Maurya, Vimal K","Prasad, Anil K","Bhatt, Madan L B","Saxena, Shailendra K"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32206694","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s13337-020-00571-5","keywords":["2019-ncov","antigenicity","covid-19","coronavirus","glycosylation","s glycoprotein","sars-cov","structural divergence"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490145865728,"score":259.55246},{"pmid":32363136,"pmcid":"PMC7194921","title":"Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.","text":["Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.","The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 A crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2.","Acta Pharm Sin B","Kang, Sisi","Yang, Mei","Hong, Zhongsi","Zhang, Liping","Huang, Zhaoxia","Chen, Xiaoxue","He, Suhua","Zhou, Ziliang","Zhou, Zhechong","Chen, Qiuyue","Yan, Yan","Zhang, Changsheng","Shan, Hong","Chen, Shoudeng","32363136"],"abstract":["The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 A crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2."],"journal":"Acta Pharm Sin B","authors":["Kang, Sisi","Yang, Mei","Hong, Zhongsi","Zhang, Liping","Huang, Zhaoxia","Chen, Xiaoxue","He, Suhua","Zhou, Ziliang","Zhou, Zhechong","Chen, Qiuyue","Yan, Yan","Zhang, Changsheng","Shan, Hong","Chen, Shoudeng"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363136","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.apsb.2020.04.009","keywords":["antiviral targeting site","covid-19","coronavirus","crystal structure","nucleocapsid protein","rna binding domain","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496012648449,"score":258.32047}]}